Novartis India

Novartis India presented a strategy built around its acquisition of the rights to use Pfizer’s Minipress trademark for ₹1,250 crore, a brand that generated ₹228 crore of revenue. The investment was funded through internal accruals and debt, while a separate agreement with NHPL carried an upfront payment of ₹10 crore for exclusive distribution and promotion of two retina products. The company described a shift from the former Dr Reddy’s Laboratories-led distribution arrangement to an in-house commercial model supported by a planned field force of more than 900 people. The DRL agreement was due to terminate on 30 September, after the company moved under ChrysCapital ownership in July. Novartis India had revenue of about ₹354 crore and net cash of ₹668 crore in FY26.

Powered by Tijori

** Pharma co Novartis India's NOIN.BO shares rise 18% to 2,580 rupees, hitting an all-time high

** Stock has gained in six of last seven trading sessions

** Gains come after co on Tuesday said it entered into an exclusive promotion and distribution agreement with Novartis Healthcare to market its retina portfolio in India

** On Monday, Novartis India said that it would acquire the Minipress brand and related IP from Pfizer PFE.N for about 12.5 billion rupees ($131.30 million)

** NOIN holds trailing 12-month PE of 55.26 vs industry median of 23.98

($1 = 95.2050 Indian rupees)

(Reporting by Abhinav Parmar in Bengaluru)

(([email protected];))

Novartis India entered into an exclusive promotion and distribution agreement with Novartis Healthcare Private Limited on 8 September 2026 for the Indian rights to Accentrix (ranibizumab) and Pagenax (brolucizumab), two retina medicines. The company agreed to pay an upfront consideration of ₹10 crore, and the arrangement was expected to support its entry into ophthalmology and expand its commercial portfolio. Novartis India had generated about ₹354 crore of FY26 revenue from pharmaceutical wholesale and trading, with no manufacturing or export revenue. Its earlier exclusive distribution and promotion agreement with Dr Reddy’s Laboratories was due to terminate on 30 September 2026.

Powered by Tijori

Sept 8 (Reuters) - Novartis India Ltd NOIN.BO:

• NOVARTIS INDIA - ENTERS EXCLUSIVE PROMOTION AND DISTRIBUTION AGREEMENT WITH NOVARTIS HEALTHCARE

• NOVARTIS INDIA - TO PAY 100 MILLION RUPEES UPFRONT CONSIDERATION TO NHPL

• NOVARTIS INDIA - CO GRANTED EXCLUSIVE RIGHTS TO PROMOTE ACCENTRIX AND PAGENAX IN INDIA

Source text: ID:nBSE1FcGcf

Further company coverage: NOIN.BO

(([email protected];;))

Novartis India's board approved the acquisition of the Minipress and Minipres trademarks registered in India and related intellectual property from Pfizer Inc. and Pfizer Products Inc. The company executed an asset purchase agreement and trademark assignment deeds on September 7 for total consideration of ₹1,250 crore, with signing and closing intended to occur simultaneously. Minipress XL, which contains prazosin and is used in India to treat hypertension and urinary symptoms of benign prostatic hyperplasia, recorded revenue of ₹228.6 crore in the July 2026 MAT period. Its sales had grown at a 6.3% compound annual rate over four years, compared with 9% for the category. Novartis India's FY26 revenue was ₹354.3 crore, and its business was entirely pharmaceutical wholesale and trading, with no manufacturing or export revenue. The company held about ₹620 crore in bank deposits and had negligible borrowings.

Powered by Tijori

Sept 7 (Reuters) - Novartis India Ltd NOIN.BO:

• TO ACQUIRE 'MINIPRESS' TRADEMARKS FROM PFIZER

Source text: ID:nBSE74jJ9y

Further company coverage: NOIN.BO

(([email protected];;))

Novartis India’s board approved the termination of its exclusive distribution and promotion agreement with Dr Reddy’s Laboratories, signed on 11 February 2022. The termination agreement was executed on 7 August 2026 and was set to take effect on 30 September, after which Novartis India was to regain exclusivity and market access for the covered products. The company’s shift to a wholesale distribution model with Dr Reddy’s had lowered revenue but improved margins. Revenue rose 18.6% year on year to ₹1,038.1 million in the first quarter of FY27, after declining in each of FY23-FY26.

Powered by Tijori

Aug 7 (Reuters) - Novartis India Ltd NOIN.BO:

• NOVARTIS INDIA - APPROVES TERMINATION OF DISTRIBUTION AGREEMENT WITH DR. REDDY’S LABORATORIES

• NOVARTIS INDIA - TERMINATION AGREEMENT WITH DR. REDDY’S EFFECTIVE SEPTEMBER 30, 2026

• NOVARTIS INDIA - TO RE-BUY EXCLUSIVITY AND MARKET ACCESS FOR PRODUCTS AFTER DRL AGREEMENT TERMINATION

Source text: ID:nBSE9P3wlf

Further company coverage: NOIN.BO

(([email protected];;))

May 12 (Reuters) - Novartis India Ltd NOIN.BO:

• NOVARTIS INDIA LTD MARCH-QUARTER PROFIT 252.5 MILLION RUPEES

• NOVARTIS INDIA LTD MARCH-QUARTER REVENUE FROM OPERATIONS 905.5 MILLION RUPEES

Source text: ID:nBSE5dBxmg

Further company coverage: NOIN.BO

(([email protected];))

March 27 (Reuters) - Novartis India Ltd NOIN.BO:

• RECEIVES TAX DEMAND OF 102.8 MILLION RUPEES

Source text: ID:nBSE8qwqlJ

Further company coverage: NOIN.BO

(([email protected];))

Adds details of deal and company background

Feb 20 (Reuters) - Swiss drugmaker Novartis NOVN.S will sell its entire 70.68% stake in its listed Indian unit NOIN.BO to a private equity-led consortium for about $159 million, as part of a broader global restructuring.

The consortium, comprising WaveRise Investments, ChrysCapital Fund X and Two Infinity Partners, will buy the stake in Novartis India through a share purchase agreement.

The group has also made a mandatory open offer to buy an additional 26% of the company at 860.64 rupees per share, a 3.6% premium to its closing price on Thursday.

Shares of Novartis India surged nearly 20% to 996.5 rupees on Friday.

The exit comes two years after Novartis began a strategic review of Novartis India, including assessing its stake in the Mumbai-based firm.

In April 2025, Novartis announced plans to spend $23 billion to build and expand in the U.S., as it faced renewed threats of drug import duties on pharmaceuticals under the Trump administration.

The Swiss company does not have a manufacturing presence in India. Novartis India primarily sells medicines, including Voveran, used to treat joint pain.

($1 = 91.0290 Indian rupees)

(Reporting by Nandan Mandayam in Bengaluru; Editing by Sonia Cheema)

(([email protected]; Mobile: +91 9591011727;))

** Shares of Novartis India NOIN.BO rise as much as 10.9% to 1,148 rupees, highest since Feb. 7, 2000

** Shares surge after CNBC-TV18 reported on Saturday that Dr Reddy's REDY.NS plans to acquire Switzerland-based pharma co Novartis AG's NOVN.S stake in Novartis India

** It added that REDY's plans to acquire the domestic-focused portfolio and may offer controlling premium

** REDY's declined to comment; Novartis India did not immediately respond to Reuters request for comment

** Shares of REDY rise as much as 2.2% to a record high of 6,454 rupees

** More than 143,000 shares of NOIN change hands, 3.4x its 30-day avg

** NOIN eyes fifth straight session of gains and has risen ~15% so far in Feb.

(Reporting by Ashna Teresa Britto in Bengaluru)

(([email protected] ; ( +91 8078332441))

Oct 27 (Reuters) - Novartis India Ltd NOIN.NS:

• NOVARTIS INDIA LTD SEPT-QUARTER PROFIT 236.8 MILLION RUPEES VERSUS PROFIT 183.5 MILLION RUPEES

• NOVARTIS INDIA LTD SEPT-QUARTER REVENUE FROM OPERATIONS 787.6 MILLION RUPEES VERSUS 1.02 BILLION RUPEES

Source text for Eikon: ID:nBSE1Z4hyD

Further company coverage: NOIN.NS

(([email protected];))

Aug 3 (Reuters) - India's drug regulator recovered counterfeit medicines worth more than 20 million rupees ($241,666) after a raid last month in the eastern city of Kolkata, the federal health ministry said on Thursday.

The raid, carried out by the Central Drugs Standard Control Organisation, found counterfeit copies of leading brands by manufacturers like Cipla CIPL.NS, Sun Pharma SUN.NS and Alkem Laboratories ALKE.NS, the health ministry said.

One person was arrested, it added.

"Further investigation to find the manufacturer and supply chain is ongoing to ensure supply of genuine medicine for consumption of general public," the health ministry said.

The medicines recovered included copies of acid reflux drugs like Pan-D and Pantocid DSR, manufactured by Alkem and Sun Pharma respectively, as well as Urimax-D, a medicine to treat an enlarged prostrate gland medicine, made by Cipla.

Authorities also recovered counterfeit copies of antibiotic medicines Augmentin and Clavam.

"Modi's government will not make any kind of compromise to stop adulterated medicines," health minister Mansukh Mandaviya said on Twitter, while congratulating the officers who carried out the raid.

The raid was the result of an investigation that began in January this year, following a complaint from Sun Pharma, when authorities recovered counterfeit medicines worth one million rupees ($12,083) the health ministry said.

($1 = 82.7590 Indian rupees)

(Reporting by Shilpa Jamkhandikar; editing by Christina Fincher)

(([email protected];))

July 26 (Reuters) - Novartis India Ltd NOIN.NS:

• JUNE-QUARTER PROFIT 202.6 MILLION RUPEES VERSUS 523.8 MILLION RUPEES

• JUNE-QUARTER REVENUE FROM OPERATIONS 906 MILLION RUPEES VERSUS 1.21 BILLION RUPEES

Source text for Eikon: ID:nBSE8w0Hpq

Further company coverage: NOIN.NS

(([email protected];))

** Shares of Novartis India Ltd NOIN.NS rise as much as 8.68% to 688.89 rupees; on track for fourth straight session of gains, if trend holds

** Pharma firm reports profit of 250.2 mln rupees ($3.1 mln) in March quarter, compared to a loss of 233.7 mln rupees a year earlier

** Approves one-time special dividend of 37.50 rupees per share and final dividend of 10 rupees per share

** Stock most active in nearly five months with a trading volume of 99,934 shares as of 10:15 a.m. IST, more than 10x the 30-day avg

** The relative strength index of the stock is 82, suggesting it may be overbought - Refinitiv data

($1 = 81.7800 Indian rupees)

(Reporting by Bharath Rajeswaran in Bengaluru)

(([email protected]; +91 9769003463))

May 10 (Reuters) - Novartis India Ltd NOIN.NS:

• MARCH-QUARTER PROFIT 250.2 MILLION RUPEES VERSUS LOSS 233.7 MILLION RUPEES

• MARCH-QUARTER REVENUE FROM OPERATIONS 761.3 MILLION RUPEES VERSUS 983.2 MILLION RUPEES

Source text for Eikon: ID:nBSE9nSYN1

Further company coverage: NOIN.NS

(([email protected];))